LMR Partners’s Elevation Oncology ELEV Stock Holding History

LMR Partners’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-31,300	Closed	-$425K	–	1052
2021 Q2	$425K	Buy	+31,300	New	+$387K	0.01%	706

Other funds holding ELEV

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

LMR Partners's ELEV Position: Q3 2021 in Review

LMR Partners sold out of Elevation Oncology (ELEV) in Q3 2021, closing a stake of 31,300 shares — an estimated $425K sold.

LMR Partners first reported a position in ELEV in Q2 2021 and held it in 1 quarter. The position peaked at $425K in Q2 2021. 22 funds tracked by Wall St. Rank hold ELEV as of Q3 2021.

LMR Partners reported no remaining Elevation Oncology position as of Q3 2021 after selling out during the quarter.
LMR Partners sold 31,300 Elevation Oncology shares in Q3 2021, an estimated $425K.
LMR Partners first reported a position in Elevation Oncology in Q2 2021 and held it in 1 quarter.
LMR Partners's Elevation Oncology position peaked at $425K in Q2 2021.
22 funds tracked by Wall St. Rank held Elevation Oncology as of Q3 2021.

Based on LMR Partners's 13F filing for Q3 2021, filed 15 Nov 2021.